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Abstract
The aim of this study was to identify circulating microRNAs (miRNAs) that could be
used as biomarkers in patients at risk for or affected by AIDS‐Kaposi's sarcoma (KS).
Screening of 377 miRNAs was performed using low‐density arrays in pooled plasma
samples of 10 HIV/human herpesvirus 8 (HHV8)‐infected asymptomatic and 10
AIDS‐KS patients before and after successful combined antiretroviral therapy (cART).
MiR‐375 was identified as a potential marker of active KS, being the most down‐
regulated in AIDS‐KS patients after cART and the most up‐regulated in naïve AIDS‐
KS patients compared to naïve asymptomatic subjects. Validation on individual
plasma samples confirmed that miR‐375 levels were higher in AIDS‐KS compared to
asymptomatic patients, decreased after cART‐induced remission in most AIDS‐KS
patients and increased in patients with active KS. In asymptomatic patients miR‐375
was up‐regulated after cART in both screening and validation. Statistical analyses
revealed an association between miR‐375 changes and CD4 cell counts, which could
explain the discordant cases and the opposite trend between asymptomatic and
AIDS‐KS patients. These data suggest that circulating miR‐375 might be a good indi-
cator of active AIDS‐KS. Moreover, changes in miR‐375 levels may have a prognos-
tic value in HIV/HHV8‐infected patients undergoing treatment. Further large‐scale
validation is needed.
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1 | INTRODUCTION
Body fluids, such as plasma, were shown to harbour highly stable,
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Received: 20 June 2018 | Revised: 9 October 2018 | Accepted: 2 November 2018
DOI: 10.1111/jcmm.14054
1486 | wileyonlinelibrary.com/journal/jcmm J Cell Mol Med. 2019;23:1486–1494.
small noncoding regulatory RNA molecules crucially involved in sev-
eral physiological and pathological cellular processes.1,2 This finding
opened up new venues for cancer diagnosis and prognosis, and cir-
culating miRNA profiles or specific miRNAs have been proposed as
informative and noninvasive biomarkers for several tumours, though
it remains to be clarified whether they originate from tumour cells or
from nonmalignant cell types as a response to the pathological sta-
tus.3
Kaposi's sarcoma (KS) is a multifocal angioproliferative soft tissue
sarcoma, involving the skin and mucosa, associated with human her-
pesvirus 8 (HHV8) infection. HHV8 is also linked to the development
of primary effusion lymphoma (PEL), a non‐Hodgkin's B‐cell lym-
phoma.4 Immunocompromised HIV/HHV8‐infected patients are at
high risk for KS. Indeed, although the incidence of AIDS‐defining
cancers has declined consistently in the era of antiretroviral therapy
(ART), KS remains 650 times more common in HIV‐infected persons
compared to uninfected subjects.5
Initial studies on PEL‐derived cell lines, KS biopsies and HHV8‐in-
fected or HHV8‐transformed endothelial cells led to the identifica-
tion of virus‐modulated or tumour‐specific cell‐associated miRNAs.6
Subsequent analyses of KS biopsies and healthy tissues provided
contrasting data, with some miRNAs showing an opposite trend.6–8
Exosomes isolated from PEL effusions, pooled plasma samples of
AIDS‐KS patients and two KS mouse models were found to deliver
HHV8‐encoded and host oncogenic miRNAs triggering cell migration
and IL‐6 release,9 highlighting their function in the context of HHV8‐
driven tumorigenesis. To date, studies aimed at identifying circulating
miRNAs as blood‐based biomarkers for KS diagnosis and prognosis
have not been carried out. To this end, we conducted a pilot study
on plasma samples of patients at risk for or affected by AIDS‐KS.
2 | MATERIALS AND METHODS
2.1 | Study population
Two groups of 10 HIV/HHV8‐seropositive patients were selected for
the initial screening: HIV‐seropositive patients with serological and
molecular evidence of HHV8 infection, and without clinical signs of
HHV8‐related and ‐unrelated pathologies, asymptomatic patients
(group A), and patients affected by AIDS‐KS (group B). Criteria for
patient inclusion were: availability of never‐thawed plasma samples
in sufficient amount at baseline (naïve) and after immunovirological
response to combined ART (cART), histological confirmation of KS
and clinical response (complete remission, CR) to cART for AIDS‐KS
patients. Seventeen patients received cART consisting of two nucle-
oside reverse transcriptase inhibitors (NRTIs) in combination with a
boosted protease inhibitor (PI), whereas three patients received two
NRTIs in combination with a non‐nucleoside reverse transcriptase
inhibitor (NNRTI). Validation included 11 asymptomatic individuals
(three belonging to the screening phase and eight newly selected),
and 11 AIDS‐KS patients (six newly selected). In addition, four AIDS‐
KS patients with disease progression (DP) or partial response (PR)
were selected (“non‐responder AIDS‐KS”), including one patient with
paradoxical KS‐associated immune reconstitution inflammatory syn-
drome (KS‐IRIS) and one patient with unmasking KS‐IRIS. These
patients received two NRTIs in combination with a boosted PI.
Blood samples were obtained after written informed consent
from patients attending the Unit of Infectious Diseases at the Gen-
eral Hospitals of Padova and Rovigo. The samples were then anal-
ysed for HHV8 infection at the Veneto Institute of Oncology.
Patients were asked to donate the residual part of the plasma sam-
ple for research purposes, as well as the residual part of previously
collected samples. The proposed research project was evaluated and
approved by the local Ethical Committee (n. 14256‐CE IOV 12/60).
2.2 | Blood sampling and immunovirological assays
Plasma was obtained from EDTA‐treated peripheral blood samples
after Ficoll‐PaqueTM PLUS (GE Health Care, Uppsala, Sweden) den-
sity gradient centrifugation. Plasma was recovered from the upper
phase and centrifuged to ensure a cell‐free specimen, and subse-
quently aliquoted and stored at −80°C until use. For the screening
analysis, plasma samples were pooled using 100 µl of plasma from
each patient included in the four categories. Each pool was prepared,
extracted, and analysed on a card, and this procedure was repeated
twice from the beginning, to have a full technical duplicate for each
group of pooled plasma. We could not perform a third replicate
because of the limited amount of some plasma samples. In the vali-
dation phase, plasma samples were individually tested for the pres-
ence of the candidate and endogenous miRNAs.
Immunovirological parameters related to HIV infection, plasma
HIV RNA, and CD4 cell counts, were assessed as previously
reported10 and expressed as log10 HIV RNA copies/mL and CD4
cells/μL, respectively.
HHV8 antibodies to a latency‐associated nuclear antigen (LANA)
were evaluated by indirect immunofluorescence, while lytic‐phase‐as-
sociated antibodies to the capsid‐related protein encoded by open
reading frame (ORF)‐65 were tested by the enzyme‐linked
immunosorbent assay (ELISA) as previously described.11 HHV8 anti-
body titres were determined using 1:50 as first dilution and
expressed as reciprocal of the highest dilution giving a positive
result. HHV8 load was determined in peripheral blood mononuclear
cells (PBMC) and saliva samples by quantitative real time‐PCR and
expressed in genome equivalents (GE).12
2.3 | RNA extraction
miRNA extraction efficiency from plasma samples (pooled or not)
was preliminarily assessed using four different methodologies: total
RNA extraction with RNA Bee (Tel‐Test Inc, Friendswood, TX, USA)
and mirVana PARIS Kit (Life Technologies, Thermo Fisher Scientific,
Waltham, MA, USA), small RNA molecule extraction with mirVana
PARIS Kit, and Nucleospin miRNA Plasma Kit (Macherey‐Nagel,
GmbH & Co, Germany). RNA concentration and purity was assessed
using Nanodrop 1000 (Thermo Scientific, Wilmington, DE, USA) and
RNA integrity using a 2100 Bioanalyzer (Agilent Technologies, Santa
PIANO ET AL. | 1487
Clara, CA, USA). RNAs extracted with the four techniques were then
analysed using the TaqMan miRNA assays (Life Technologies,
Thermo Fisher Scientific, Carlsbad, CA, USA) specific for U6 and
RNU48. On the basis of RNA purity, integrity, and amplification
plots, we selected the Nucleospin miRNA Plasma Kit as the most
efficient method to extract total plasmatic miRNAs, including those
incorporated into exosomes, according to the manufacturer's instruc-
tions. Total RNA, enriched in low molecular weight molecules, was
therefore extracted using NucleoSpin miRNA columns from the
pooled plasma belonging to each group. RNA concentration, purity,
and integrity were evaluated as described above. Extracted RNA was
then analysed for U6 using a TaqMan microRNA assay (Life Tech-
nologies) to further evaluate the quality and miRNA amplication of
the extracted small‐sized RNA fraction.
2.4 | Statistical analysis
Only measurable samples were considered for descriptive purposes
whereas data under the detection level were replaced with a con-
stant value (40 for HIV viraemia, 4.5 GE for HHV8 viral load, 45 for
HHV8 antibody titres) for statistical analysis purposes.
All patient characteristics before and after therapy were summa-
rized as median and interquartile range expressed as (Q1;Q3), and
compared using the Kruskal‐Wallis test to assess whether the
screening and validation datasets had the same median.
The differential distribution of all parameters at baseline, after
therapy and their change from baseline, between AIDS‐KS and
asymptomatic patients was assessed by the Kruskal‐Wallis test, and
the pairwise comparisons between levels at baseline and after ther-
apy within each group of patients was based on the Wilcoxon signed
rank test.
The association between all parameters and RQ levels, dichoto-
mized as higher and lower than 1, was verified with the Kruskal‐Wal-
lis test. All statistical tests used a two‐sided 5% significance.
Statistical analyses were performed using the SAS statistical package
(SAS, rel. 9.4; SAS Institute Inc).
2.5 | miRNA profiling
Global miRNA profiling was performed by real‐time quantitative PCR
using an ABI Prism 7900HT sequence detector system (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA USA). Reverse
transcription using 500 ng of total RNA was performed using the
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) in
combination with the Megaplex RT human Primers Pool A (Applied
Biosystems) according to the manufacturer's protocol. cDNA was
loaded onto 384 well TaqMan low‐density arrays (Human MicroRNA
Array A, panel v2.0, Applied Biosystems) for the study of 377 well‐
known and highly characterized miRNAs. Amplification results were
analysed with SDS 2.4 and RQ Manager 1.2.1 (Life Technologies).
The amplification curves were individually inspected and miRNAs
with abnormal amplification patterns were removed from analysis.
Undetermined Ct values were set to a maximum value of 40. All the
miRNAs whose Ct standard deviation exceeded the 75‐th percentile
of the observed standard deviation distribution were not considered
in the differential expression analysis, in order to control the number
of unreliable discoveries due to technical variability.
The three miRNAs expressed in all the four conditions and show-
ing the lowest standard deviation of raw Ct values were selected as
candidate endogenous references. Relative expression of target miR-
NAs was calculated as ΔCtmiRNA = CtmiRNA – Ctendogenous reference.
Differential expression of each miRNA was then expressed as
ΔΔCtmiRNA = ΔCtmiRNAtreated – ΔCtmiRNAnaïve, by subtracting from the
ΔCt of a specific miRNA in group “treated” the ΔCt of that miRNA
in group “naïve”. The fold change (FC) was calculated as 2–ΔΔCt
assuming a PCR amplification efficiency of 100%.13 Analyses of Taq-
Man low‐density array microRNA data were performed in the R soft-
ware suite.
2.6 | qRT‐PCR validation
Validation analysis for the selected miRNAs was performed by quan-
titative real‐time RT‐PCR in 11 individual plasma samples from each
group. miRNA‐specific reverse transcription of 10 ng RNA for each
sample was performed using the TaqMan MicroRNA Reverse Tran-
scription Kit (Applied Biosystems) and cDNA were amplified using
specific miRNA TaqMan assays (miR‐375 ID: 000564; miR‐92a ID:
000431) according to the manufacturer's instructions. The assays
were performed in duplicate on the ABI 7900HT RealTime PCR sys-
tem (Applied Biosystems). miR‐375 relative quantification (RQ) was
done using miR‐92a as endogenous control with the 2–ΔΔCt
method13: 2–ΔΔCt = 2–[ΔCtmiRNA (treated) – ΔCtmiRNA (naïve)]. Normaliza-
tion based on the global mean was performed as previously
described.14
3 | RESULTS
3.1 | Analysis of patient characteristics
Twenty HIV/HHV8‐infected patients were selected for the initial
screening and included 10 asymptomatic patients (group A), naïve
and cART‐treated, and 10 AIDS‐KS subjects (group B), naïve and
cART‐treated; 22 HIV/HHV8‐infected patients were selected for the
validation phase and included 11 asymptomatic subjects (group A),
naïve and cART‐treated, and 11 AIDS‐KS subjects (group B), naïve
and cART‐treated. Demographics and immunovirological parameters
of all study patients are reported in Table 1.
No statistically significant differences in all variables, at baseline
and after therapy, were found between screening and validation
datasets (Table 1).
All variables were then compared between asymptomatic and
AIDS‐KS patients, at baseline and after treatment (Table S1). CD4
cell counts were found to be significantly higher in cART‐treated
asymptomatic subjects compared to cART‐treated AIDS‐KS patients
in both the screening (median [Q1;Q3], 650 [408;687] vs 343.5
[194;432], P = 0.0233) and validation (671 [507;721] vs 390
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[181;620], P = 0.0385) datasets, whereas HIV RNA loads did not sig-
nificantly differ in each comparison. Concerning HHV8‐related
parameters, a higher HHV8 load was observed in treated AIDS‐KS
patients compared to treated asymptomatic patients in the screening
set, but the difference did not reach significance. HHV8 antibody
titres were significantly higher before and after treatment in AIDS‐
KS patients compared to asymptomatic patients of the screening
and validation groups, with the exception of LANA antibody levels
between naïve AIDS‐KS and asymptomatic patients of the screening
group (Table S1). Treatment duration was longer in asymptomatic
compared to AIDS‐KS patients, but the difference was significant
only in the validation group (screening: median months [Q1;Q3],
20.5 [12;25] vs 10 [7;13], P = 0.0628; validation: 19 [14;28] vs 9
[6;14], P = 0.0103).
Analysis of the changes after treatment (Table S1) indicated that
antibody titres against ORF65 significantly increased in AIDS‐KS
patients compared to asymptomatic patients in both screening
(P = 0.0305) and validation (P = 0.0076) groups. Conversely, the
increase in CD4 cell counts was significantly higher in asymptomatic
patients compared to AIDS‐KS patients after treatment only in the
screening (344.5 [174;386] vs 113.5 [80;160] P = 0.0025).
On the whole, these analyses indicated that screening and valida-
tion datasets did not differ for the considered variables, and that
CD4 cell counts and HHV8 antibody titres were significantly differ-
ent between treated asymptomatic and AIDS‐KS patients in screen-
ing and validation datasets.
3.2 | Screening by low‐density arrays and
identification of a candidate miRNA
Selected patients had a successful cART response, with a statistically
significant decrease in HIV viraemia and a significant increase in
CD4 cell counts (see Figure S1). Moreover, ORF65 antibody titres
significantly increased in AIDS‐KS patients after treatment (Wilcoxon
signed rank test, P = 0.0156), whereas all other parameters did not
statistically change (not shown).
TaqMan low‐density arrays were used to screen 377 miRNAs in
plasma samples, which were pooled to look for substantial character-
istics of each patient group and to reduce differences due to sub-
ject‐to‐subject variation.
To identify stably expressed miRNAs to be used as endogenous
controls, Ct variability of each miRNA across the different groups of
patients was evaluated. Among the detectable miRNAs with Ct < 30,
miR‐92a, miR‐320 and miR‐484 were the three most stable and were
selected as reference miRNAs to normalize the Ct values of the
remaining miRNAs in the cards. Differentially expressed miRNAs
found in each comparison were consistent, independently from the
chosen reference miRNA.
By comparing the miRNA profiles at baseline, that is naïve AIDS‐
KS vs asymptomatic patients, 53 miRNAs were found to be differen-
tially expressed (Table S2). Among the modulated miRNAs, two were
up‐regulated in AIDS‐KS subjects and 51 down‐regulated (Figure 1A).
cART response led to the modulation of 20 circulating miRNAs in
asymptomatic patients; 15 were down‐regulated and 5 up‐regulated
compared to baseline levels (Figure 1A and Table S3). Successful
treatment in AIDS‐KS patients was associated with downmodulation
of 6 miRNAs and up‐regulation of 11 miRNAs (Figure 1A and
Table S4).
Among the differentially expressed miRNAs before and after
cART, miR‐375 was one of the most markedly up‐regulated miRNAs
in asymptomatic subjects (FC > 100) and the most markedly down‐
regulated in AIDS‐KS patients (FC < –33) (Tables S3‐S4 and Fig-
ure 1A). Moreover, miR‐375 was the most up‐regulated (FC > 9)
between naïve AIDS‐KS and naïve asymptomatic patients (Table S2
and Figure 1A). Therefore, miR‐375 was selected as a candidate
miRNA with a potential prognostic value for further validation.
3.3 | Validation
Patients selected for the validation showed a successful response to
treatment, with a statistically significant decrease in HIV viraemia
and a significant increment in CD4 cell counts (Figure S1). Pairwise
comparison did not evidence statistically significant changes in all
other parameters (not shown).
Validation was carried out by measuring miR‐375 levels in indi-
vidual plasma samples. Among the three miRNAs found to be the
most stable, miR‐92a was selected as reference miRNA to normalize
miR‐375.
Comparison of the relative levels of miR‐375 among all four
patient categories is shown in Figure 1B. Median levels of miR‐375
were higher in AIDS‐KS patients compared to asymptomatic sub-
jects, suggesting that high levels of miR‐375 may be an indicator of
active KS.
We then analysed validation data on individual patients with the
same procedure used for the screening (fold change computation),
and obtained the following results: naïve AIDS‐KS vs naïve asymp-
tomatic patients, FC = 4.77; treated AIDS‐KS vs naïve AIDS‐KS, FC =
–2.24; treated asymptomatic vs naïve asymptomatic, FC = 2.44.
Albeit the levels of modulation were lower, trends observed in the
screening were confirmed.
To better describe the modulation of miR‐375 during patient fol-
low‐up, relative quantification (RQ) in each individual plasma of
cART‐treated patients was calculated with respect to baseline, naïve
condition (having an RQ = 1). Therefore RQ > 1 indicates miR‐375
up‐regulation, whereas RQ < 1 miR‐375 down‐regulation. As shown
in Figure 1C, miR‐375 increased after cART in 9 of 11 asymptomatic
patients (RQ > 1). Among the 11 AIDS‐KS patients showing com-
plete clinical remission, seven demonstrated decreased levels of cir-
culating miR‐375 (RQ < 1), whereas four had RQ > 1 (Figure 1C). To
explain the discordant RQ values of the two asymptomatic patients
and the four AIDS‐KS patients, we stratified all subjects according to
RQ values > or <1, and analysed all the characteristics related to
these patients. Interestingly, we found an association between RQ
levels and CD4 cell counts. AIDS‐KS patients in trend with the
screening, with RQ < 1, had significantly lower CD4 levels compared
to AIDS‐KS patients not in trend, with RQ > 1, both at baseline
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(P = 0.0230) and after treatment (P = 0.0140) (Table 2, and data not
shown). Conversely, asymptomatic patients showed the opposite (in
trend with the screening, RQ > 1 and lower CD4 cell count; not in
trend, RQ < 1 and higher CD4 cell count), although differences were
not statistically significant (Table 2). Therefore, although limited to a
small cohort, these findings might explain the distribution of RQ
according to the CD4 levels.
In summary, validation carried out in individual plasma samples
of HIV/HHV8‐infected patients in follow‐up confirmed the trends
observed in the screening for most patients. Moreover, statistical
analyses revealed an association between RQ levels and CD4 cell
counts, thus explaining the discordant results. Therefore, these find-
ings suggest that levels of miR‐375 might have a prognostic value in
cART‐treated patients and might be associated with CD4 cell counts.
3.4 | Analysis of miR‐375 in non‐responder AIDS‐
KS patients
To further test the prognostic value of miR‐375 in AIDS‐KS patients,
two patients with clinical PR and subsequent CR, and two patients
with DP, who developed KS‐IRIS, were included in the follow‐up
analysis (Table 1). As reported in Figure 1C, two patients showed
increased levels of miR‐375 during PR (RQ > 1) (x and solid circle),
F IGURE 1 Modulated circulating miRNAs in the different patient
groups of the screening analysis and validation of the candidate
miRNA. A, The screening was conducted by analysing the expression
levels of 377 miRNAs in HIV/HHV8‐infected patients, without and
with Kaposi's sarcoma, before (naïve condition) and after successful
antiretroviral treatment (cART‐treated). The number of modulated
miRNAs found in each comparison of interest (naïve B vs naïve A,
cART‐treated A vs naïve A, and cART‐treated B vs naïve B) are
reported in each box. Circulating miR‐375, one of the most markedly
modulated miRNA after cART, was chosen as candidate prognostic
miRNA for subsequent validation. Reported fold changes of miR‐375
are calculated using miR‐92a as reference. B, Comparison of the
levels of circulating miR‐375 in individual plasma of the four
categories of patients. In the validation phase, naïve AIDS‐KS
patients showed the highest median level of miR‐375 compared to
the other three patient categories, suggesting that this miRNA might
be indicative of active KS. Significant variations are indicated
(Wilcoxon rank‐sum test). Cross symbols indicate the mean values.
nRQ: normalized relative quantification. C, Variation of miR‐375
expression in patients analysed after successful cART and in AIDS‐
KS patients not responding to therapy. In this graph, the expression
level (RQ) is normalized with respect to the naïve condition: RQ > 1
is therefore indicative of increasing miR‐375 levels, whereas RQ < 1
indicates decreasing miRNA levels with respect to the baseline
condition. MiR‐375 up‐regulation was found in most asymptomatic
patients, whereas most AIDS‐KS patients showed miR‐375 down‐
regulation, confirming the trend observed in the screening by low‐
density arrays. On the right‐hand side of the Figure, 4 non‐
responder AIDS‐KS patients were analysed in follow‐up (indicated
with t for different time‐points after cART). Two AIDS‐KS patients (x
symbol and solid circle) during partial response (PR) showed RQ > 1,
and subsequently RQ < 1 following complete remission (CR). A
patient with disease progression (DP) who developed paradoxical
KS‐IRIS (triangle down) showed an up‐regulation of miR‐375,
whereas a patient with unmasking KS (solid square) did not follow
this trend (RQ < 1). These data indicate that circulating miR‐375
levels are down‐regulated in AIDS‐KS patients with complete clinical
response, whereas they increase in patients not responding to cART,
suggesting that circulating miR‐375 might be an indicator of active
KS in AIDS patients
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and their RQs became <1 after CR. The patient who had paradoxical
KS‐IRIS (triangle down) during cART showed an up‐regulation of
miR‐375 (RQ > 1), whereas the patient with unmasking KS‐IRIS
(solid square) did not follow this trend. As the unmasking condition
is the development of KS during cART, the decrease in miR‐375
levels is the result of a transition between two rarely subsequent
conditions, from naïve asymptomatic to cART‐treated AIDS‐KS. The
comparison of cART‐treated AIDS‐KS vs naïve asymptomatic was
carried out using low‐density array data (not shown) and gave the
following negative fold changes with respect to the three normaliz-
ers: −2.56; −5.49; −3.17, suggesting that this rare manifestation of
the disease might indeed be accompanied by a decrease in miRNA‐
375.
Although limited to three non‐responder AIDS‐KS patients anal-
ysed in follow‐up during cART, these data might suggest that the
persistence of high levels of miR‐375 in KS patients may be indica-
tive of active disease.
4 | DISCUSSION
Mir‐375 was previously shown to be involved in tumorigenesis, as it
was found to be dysregulated in different tumour types, with levels
of expression mainly down‐regulated in tumour tissues, suggesting
that it may function as an oncosuppressor.15,16 Conversely, circulat-
ing miR‐375 levels were found to be mainly increased in cancer
patients,17–19 suggesting that miR‐375 may be indicative of onco-
genic activity. In virus‐induced tumours, miR‐375 was shown to be
up‐regulated in the peripheral compartment and in tumour tissues of
Merkel cell carcinoma, indicating that circulating miR‐375 might be
released by the tumour.20,21 On the other hand, patients affected by
hepatocellular carcinoma were found to have deregulated miR‐375
levels in neoplastic tissues and in serum samples, but the direction
of dysregulation and virus association remain controversial.19,22,23
MiR‐375 was not reported to be among the miRNAs modulated
in KS tissues.6–8 However, a common finding is a remarkable miRNA
down‐regulation,6–8 involving also miRNAs acting as tumour suppres-
sors, such as members of the let‐7 family. Our screening analysis
showed that KS development in naïve patients is associated with
downmodulation of many circulating miRNAs (Table S2 and Fig-
ure 1A), indicating a similar scenario in plasma and tumour. These
data suggest that KS tumour and the other cell/s releasing miRNAs
in the systemic compartment respond to similar signals, leading to
miRNA shutdown. Consistently, two circulating miRNAs found in the
screening, let‐7e and miR‐20a, were previously shown to be down‐
regulated also in KS tissues.6,8
The screening analysis on pooled plasma samples indicated miR‐
375 as the most down‐regulated in AIDS‐KS patients and markedly
up‐regulated in asymptomatic subjects after successful cART (Fig-
ure 1A). The validation carried out on individual plasma samples con-
firmed this opposite trend in most patients. MiR‐375 might be
released by circulating cells and/or tissue reservoirs influenced by
the tumorigenic activity and, possibly, by different signals in the
absence of the neoplasia. In HIV/HHV8‐infected patients, regulation
of miR‐375 levels might be affected by immunovirological parame-
ters linked to HIV infection and by factors associated with HHV8,
which differ between asymptomatic and AIDS‐KS patients. Statistical
analyses showed that, after cART, CD4 cell counts in asymptomatic
patients were significantly higher compared to AIDS‐KS patients in
both screening and validation (Table S1). Despite the different ther-
apy interval, this is in line with the lower CD4 cell recovery observed
in HIV patients with more advanced immunodeficiency.24 Moreover,
HHV8 antibodies titres were significantly higher in cART‐treated
AIDS‐KS patients compared to asymptomatic subjects (Table S1), a
finding consistent with the higher amount of lytic and latent antigens
that the immune system encounters in patients with KS tumour
compared to tumour‐free subjects. Indeed, HHV8 load, in PBMC and
mainly in saliva, was higher in treated AIDS‐KS patients compared to
asymptomatic patients, but the difference did not reach statistical
significance (Table S1). Furthermore, analysis of the distribution of all
patient characteristics according to the RQ levels demonstrated an
association between RQ and CD4 levels (Table 2), that was statisti-
cally significant in naïve and treated AIDS‐KS patients. The associa-
tion of miR‐375 changes and CD4 cell counts might explain the
opposite trend between asymptomatic and AIDS‐KS patients and the
TABLE 2 Analysis of CD4 cell count distribution according to RQ values of miR‐375
CD4 cell count (cells/µL)
Asymptomatic AIDS‐KS
RQ < 1 (n = 2) RQ > 1 (n = 9)
P value
RQ < 1 (n = 7) RQ > 1 (n = 4)
P valueMedian (Q1;Q3) Median (Q1;Q3) Median (Q1;Q3) Median (Q1;Q3)
Naïve 657.5 (452;863) 345 (285;378) 0.0593 90 (50;230) 342.5 (241;571.5) 0.0230
cART‐treated 957 (606;1308) 671 (507;721) 0.3447 333 (160;390) 680 (511;745) 0.0140
Δ(Treated‐Naïve) 299.5 (154;445) 359 (80;410) 0.6374 160 (−20;264) 233.5 (100;343.5) 0.5074
CD4 cell counts are expressed as the median and interquartile range. RQ > 1 indicates miR‐375 up‐regulation and RQ < 1 indicates miR‐375 down‐reg-
ulation. The association between all parameters and RQ levels, dichotomized as higher and lower than 1, was verified with the Kruskal‐Wallis test. Naïve
and cART‐treated AIDS KS patients showing down‐regulation of circulating miR‐375 (RQ < 1) had statistically significant lower amounts of CD4 lympho-
cytes compared to patients with RQ > 1. Naïve and cART‐treated asymptomatic patients with RQ > 1 had lower amounts of CD4 cells compared to
patients with RQ < 1, although differences were not significant. These data, although limited to a few patients, suggest that modulation in the circulat-
ing amounts of miR‐375 may be associated with CD4 cell counts.
RQ, relative quantification; n, number of samples; Q1, first quartile; Q3, third quartile; cART, combined antiretroviral therapy; Δ(Treated‐Naïve), difference
between cART‐treated and naïve condition.
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discordant cases. Overall, our results suggest that circulating miR‐
375 might have a prognostic value in cART‐treated patients, and that
CD4 lymphocytes might be involved in miR‐375 regulation in HIV/
HHV8‐infected subjects.
Validation results also indicated that circulating miR‐375 levels
were higher in AIDS‐KS patients compared to asymptomatic
patients, regardless of treatment (Figure 1B). Moreover, while
tumour regression was associated with decreased miR‐375 levels
(RQ < 1, Figure 1C) in AIDS‐KS patients with lower CD4 cell counts,
at both baseline and after treatment (Table 2), tumour persistence
during PR or DP in non‐responders was associated with up‐regulated
miR‐375, suggesting that this miRNA could be a circulating marker
of tumour activity. The patient that during DP showed decreased
miRNA levels (RQ < 1) was a case of unmasking KS‐IRIS. The differ-
ent trends shown by the two KS‐IRIS patients might be influenced
by the different clinical presentation of this rare inflammatory condi-
tion, as paradoxical KS‐IRIS is characterized by the worsening of a
pre‐existing tumour whereas unmasking KS‐IRIS leads to the devel-
opment of KS, both in the context of a sudden immune reconstitu-
tion during cART.25 In the screening phase, the comparison of cART‐
treated AIDS‐KS vs naïve asymptomatic patients showed a down‐
regulation of miR‐375, consistently with the patient with unmasking
KS‐IRIS, suggesting that this rare KS presentation might indeed lead
to decreased miR‐375 amounts.
In conclusion, results of this pilot study suggest that circulating
miR‐375 may have a prognostic value in HIV/HHV8‐infected
patients, and might be influenced by CD4 cell counts. Moreover,
miR‐375 might represent a good indicator for active KS in AIDS
patients. Further studies in larger cohorts of patients are warranted
to confirm these preliminary data.
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